Telix reaffirms over 25% Precision Medicine revenue growth target for 2026
Telix Pharmaceuticals reported U.S. dose volumes up 1% quarter on quarter in Q3 2026, received FDA approval for Pixclara and kept its 2026 outlook.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Telix Pharmaceuticals (TLX) published its third-quarter 2026 update, according to a press release distributed via GlobeNewswire. U.S. dose volumes for Gozellix and Illuccix rose 1% compared with the previous quarter.
The company also said the FDA approved Pixclara, opening a new neuro-oncology imaging line, and announced a planned merger with ITM. Management reiterated that revenue from its Precision Medicine segment should grow by more than 25% in 2026.
why it matters
The confirmed growth outlook matters for investors, but the modest quarterly dose gain hints at seasonal softness into the fourth quarter. The merger terms and timing are not disclosed in the text, so its effect on the company's valuation remains unclear.
tags
instruments
sources
- Telix Pharmaceuticals Limited (TLX) Issues Q3 Update, Reaffirms 2026 PM Growth Target — globenewswire.com, 20 October 2026 at 22:10 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗